

Bacterial contamination of propofol vials: The second report from Turkey

Zeynep Ergenc¹, Hasan Ergenc^{1*}, Fatih Bostancı², Fuat Ekiz³, Gülşah Baycelebi⁴, Feyzi Gokosmanoglu⁵

1 Department of Internal Medicine, Ayancık Government Hospital, Sinop, TR

2 Department of Infectious Diseases and Clinical Microbiology, Medical Park Hospital, Ordu, TR

3 Department of Gastroenterology, Medical Park Hospital, Ordu, TR

4 Department of Internal Medicine, Atasam Hospital, Samsun, TR

5 Department of Endocrinology and Metabolic Diseases, Medicana International Hospital, Samsun, TR

* Corresponding Author: Hasan Ergenc E-mail: dr.hasanergenc@hotmail.com

ABSTRACT

Objective: In this study, we look at the case report of an outbreak of sepsis in patients who underwent upper gastrointestinal endoscopy or colonoscopy during three consecutive days. Twelve patients had diagnostic procedures in the endoscopy unit between 05 May 2018 and 07 May 2018. Of the 12 patients, three had upper gastrointestinal endoscopy, six had a colonoscopy, and three had a combination of two procedures. Within two days of discharge, five patients diagnosed with SIRS and referred with fever as the major sign were hospitalized to the infectious diseases clinic. In our Endoscopy Unit, media, drug, and material cultures were taken for microbiological analysis, and microbial agents were searched. Growth was detected only in the propofol drawn into the syringe that was used on the patient. This study highlights the importance of strict compliance with aseptic injection guidance and constant analysis of microbiological data

Keywords: Propofol vial, Contamination

INTRODUCTION

There are many benefits to using propofol over other intravenous anesthetics, benefits such as early onset and rapid elimination, fewer side effects, and short duration of action (1). Propofol lipid emulsion can be associated with microbiological contamination, which has two sources: intrinsic, which comes from the manufacturing environment, or extrinsic, which happens after opening the vial, and extrinsic contamination is usually more common (2). Although microbiological contamination has sometimes led to the outbreak of sepsis and postoperative infections in the United States and developed countries (3), it has not received much attention in developing countries and Turkey. As far as we know, in Turkey, only one study has been conducted on propofol contamination and its clinical significance. Problems and deficiencies in aseptic techniques can lead to viral or bacterial infections. Suppose a contaminated solution is injected into a patient. In that case, the symptoms of sepsis can appear in less than a few hours and can even be fatal to the patient (4). One of the opportunistic bacterium seen in cases of bacterial and wound infection outbreak is *Serratia marcescens* (5). Due to the high crude mortality rate of bacteremias (about 35% to 60%), these infections should be taken seriously (6, 7). In this study, we look at the case report of an outbreak of sepsis in patients who underwent upper gastrointestinal endoscopy or colonoscopy during three consecutive days.

MATERIAL and METHODS

This study has been conducted using the Helsinki Declaration's principles and approved by the local Institutional Review Board.

Twelve patients had diagnostic procedures in the endoscopy unit between 05 May 2018 and 07 May 2018. Of the 12 patients, three had upper gastrointestinal endoscopy, six had a colonoscopy, and three had a combination of two procedures. All patients were discharged on the same day after successful, uncomplicated procedures.

Sepsis diagnosis was based for the patients who were isolated *S. marcescens* from blood culture and met two or more from the following four parameters over three hours: 1) fever ($>38^{\circ}\text{C}$); 2) leucocytosis ($>12 \times 10^9/\text{L}$) or leucopenia ($<4 \times 10^9/\text{L}$) or $>10\%$ immature (band) forms; 3) tachycardia (> 90 beats per minute); 4) tachypnoea (> 20 breaths per minute) or hyperventilation ($\text{pCO}_2 < 4.3 \text{ kPa}$) .8

Case Report Article

Received 29-10-2022

Accepted 24-11-2022

Available Online: 27-11-2022

Published 30-11-2022

Distributed under
Creative Commons CC-BY-NC 4.0

OPEN ACCESS



Statistics

Statistical analyzes were performed with SPSS Version 22.0 (SPSS Inc, Chicago, IL, USA). Chi-brothers to design what each could be. Very convenient logistic regression analyzes were performed for predictors of culture positives. Statistical influences are included in the regression analysis. Statistically, $P < 0.05$ was considered significant.

RESULTS

Within two days of discharge, five patients diagnosed with SIRS and referred with fever as the major sign were hospitalized to the infectious diseases clinic. The patient was hospitalized, and their vitals were checked. Antibiotic treatments were started. The fever subsided within 48-72 hours. Meropenem-Levofloxacin was used for their treatments. During admission, mean values (range) for white blood cell, C-reactive protein, aspartate aminotransferase, alanine aminotransferase, urea, and creatinine of SIRS patients were respectively 22900 mg/L (range, 3600 to 39000), 7.8 mg/L (range, 0.27 to 13), 77.3 U/L (range, 13 to 172), 65.4 U/L (range, 14 to 212), 30 mg/dl (range, 15 to 41), 1.14 $\mu\text{mol/L}$ (range, 0.66 to 1.92). Demographic and laboratory characteristics of patients are shown in **Table 1**.

Four of these five SIRS patients had positive blood cultures with *S. marcescens*, and all strains were uniformly susceptible to meropenem (MICs < 0.25 mg/l) and levofloxacin (MICs < 0.25 mg/l).

Cultures were obtained from the environment, water, and surfaces in the endoscopic intervention room and shown in **Table 2**.

In propofol, *S. marcescens* was identified. Endoscopic procedures were not performed on the same day but on different days and times. Propofol serial number 17382033 used in all cases with culture was removed. Closed propofol vials of the same batches were correspondingly cultured and found sterile. Incident notification to the “Ministry of Health” and “Turkey Pharmaceuticals and Medical Devices Agency” was performed.

Following obtaining samples from possible infection sources, further use of the endoscopy unit was suspended for three days. After consulting and receiving the opinions of the anesthesiologist and other personnel in the unit, the mentioned problems were noted. A written protocol for daily cleaning included three cleaning stages at the beginning of the day, between operations, and at the end of the day. New instructions for storing, preparing, and using medications were also introduced. Determining which materials should be stored in the endoscopy unit was the responsibility of the hospital infection control team, and infection control procedures were instructed for the theatre personnel.

The endoscopy unit was suspended for three days after obtaining samples from possible infection sources. Opinions and suggestions of the anesthesiologist, technician, and other healthcare professionals working in the endoscopy unit were taken, and the problems they emphasized regarding their daily work routines were noted. A new guide has been created to prepare, store, and use drugs handled in the clinic. A new protocol has also been developed for cleaning measures to be performed before, between, and after endoscopic procedures. The in-hospital infection control committee determined the materials and drugs to be kept and excluded in the endoscopy unit. The staff of the endoscopy unit was informed about infection control procedures.

Table 1. Demographic and laboratory characteristics of patients

Operations	Patient 1 Endoscopy/Colonoscopy/Endoscopy Biopsy	Patient 2 Endoscopy/Colonoscopy/Endoscopy Biopsy	Patient 3 Colonoscopy/Biopsy	Patient 4 Flexible Sigmoidoscopy	Patient 5 Colonoscopy
First-day WBC	38.000	39.000	13.000	3.600	21.000
Third-day WBC	26.000	40.000	6.000	24.000	9.00
Fifth-day WBC	9.000	16.000	2.96	Discharged	Discharged
First-day CRP	13	5.97	8.8	0.27	11
Third-day CRP	7	13.85	15.3	11.87	10
Fifth-day CRP	1.13	6.72	2.96	Discharged	Discharged
First-day AST/ALT	19/14	105/61	13/14	23/26	172/212
Third-day AST/ALT	22/16	45/50	26/18	86/80	65/122
Fifth-day AST/ALT	20/16	17/27	52/46	Discharged	Discharged
First-day urea/creatinine	39/0.84	41/1.26	21/10.2	34/1.92	15/0.66
Third-day urea/creatinine	26/0.71	64/108	13/0.86	68/4.46	11/0.63
Fifth-day urea/creatinine	28/0.72	41/0.75	11/0.65	Discharged	Discharged

Table 2. Cultured sources in the endoscopic intervention room

Source	Organism
Vial of propofol in use	<i>Serratia marcescens</i>
Unopened vials of propofol	Negative
Disinfectant in use	Negative
Unopened disinfectant	Negative
Water from the suction system	Negative
Endoscopic channel	Negative
Colonoscopic channel	Negative

DISCUSSION

To our knowledge, this is the second report of its kind in Turkey. In 2019, Cilli et al. reported an outbreak of sepsis caused by propofol contaminated with *S. marcescens* in three patients (4).. Although propofol has been used in Turkey since 1990, no sepsis outbreaks of sepsis have been reported since then. However, generally accepting sepsis as a surgical complication can cause an outbreak to be undiagnosed.

In our Endoscopy Unit, media, drug, and material cultures were taken for microbiological analysis, and microbial agents were searched. Growth was detected only in the propofol drawn into the syringe that was used on the patient. Patients were hospitalized in the Infectious Diseases Clinic by making their first interventions in the Emergency Service. Infection Control Committee meeting was held, and the clinical status of the patients and the precautions to be taken were discussed. The high-level disinfectant effectiveness check was repeated, and positive results were obtained.

The first outbreak reported due to contaminated propofol was published in 1992 and was a surgical field infection caused by *S. aureus* in the USA (3). In the literature, twenty propofol-related outbreaks have been reported to date. In these outbreaks, 144 cases were infected, and 10 patients died. Four outbreaks involving *S. marcescens* have found their place in the literature, and the 5th reported outbreak is this study (9). In 2014, Ersoz et al. reported a meningitis outbreak because of *S. marcescens* after spinal anesthesia (10). In 2017, Us et al. reported an outbreak of soft tissue and wound infection of *S. marcescens* in subjects undergoing wound care (11)

Medications and parenteral solutions contamination by *S. marcescens* have been the source of prior hospital-acquired infection outbreaks (12). Prefilled syringes, prepared solutions, and Multi-dose vials are essential infection tools (13, 14). *S. marcescens* can cause bacteremia, respiratory infections in ICU, and surgical site infections after invasive procedures (14, 15). In the present study, a previously prepared anesthetic drug is contaminated with *S. marcescens*. The main problem in this outbreak was re-using vials and standard syringes that may have caused contamination during the outbreak. In the post-outbreak evaluation, it was observed that some drugs were used a few days after they were prepared, in violation of hospital policies. In a performance-based payment system in Turkey, it is expected from the surgeons to make more surgery. Anesthesiologists have a short time to provide medicines between surgeries, which can sometimes fail to comply with basic infection control measures. Also, it was not practical to use disposable propofol bottles as “single-use.”

One of the limitations of this study is that all the data in this study came from one institution, and some related details of the influencing factors and event histories may not be adequately documented, which may affect the outcome. Therefore, interpretations of the results of this study should be made with caution.

CONCLUSION

Outbreaks caused by contaminated propofol continue to find a place in the literature. In the outbreak presented in this study, *S. marcescens* was separated from an opened propofol bottle and salt solution in the garbage and various syringes filled with propofol. Cultures made in unopened propofol ampoules were found sterile. This study highlights the importance of strict compliance with aseptic injection guidance and constant analysis of microbiological data.

Acknowledgments: None

Conflict of interest: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research did not receive and specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contributions: Conceptualization: Ergenc H, Ergenc Z, Bostancı F, Ekiz F. Data curation: Gokosmanoglu F, Ergenc H. Formal analysis: Ergenc H, Ergenc Z, Gokosmanoglu F. Investigation: Ergenc Z, Ergenc H, Baycelebi G, Gokosmanoglu F. Software and validation: Ergenc H, Ergenc Z, Gokosmanoglu F. Methodology: Ergenc H, Ergenc Z. Resources: Ergenc Z, Gokosmanoglu F. Writing-original draft: Ergenc Z. Writing - review&editing: : Ergenc H, Ergenc Z, Gokosmaoglu F, Ekiz F, Bostancı F, Baycelebi G.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the institutional and/or national research committee's ethical standards and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

REFERENCES

1. Arduino MJ, Bland LA, McAllister SK, Aguero SM, Villarino ME, McNeil MM, et al. Microbial growth and endotoxin production in the intravenous anesthetic propofol. *Infect Control Hosp Epidemiol* 1991;12:535-9. PMID: 1940276.
2. Centers for Disease Control and Prevention. Postsurgical infections associated with an extrinsically contaminated intravenous anesthetic agent e California, Illinois, Maine, and Michigan, 1990. *MMWR Morb Mortal Wkly Rep* 1990;39:426-7. PMID: 2113169.
3. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, Perrotta DM, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. *N Engl J Med* 1995;333:147-54. PMID: 7791816.
4. Cilli F, Nazli-Zeka A, Arda B, Sipahi OR, Aksit-Barik S, Kepeli N, et al. *Serratia marcescens* sepsis outbreak caused by contaminated propofol. *Am J Infect Control*. 2019;47(5):582-4. PMID: 30527282.
5. Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of *Serratia marcescens* associated with the anesthetic agent propofol. *Am J Infect Control* 2001;29:312-5. PMID: 11584257.
6. Tallis GF, Ryan GM, Lambert SB, Bowden DS, McCaw R, Birch CJ, et al. Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules. *J Viral Hepat* 2003;10:234-9. PMID: 12753344.
7. Muller AE, Huisman I, Roos PJ, Rietveld AP, Klein J, Harbers JB, et al. outbreak of severe sepsis due to contaminated propofol: lessons to learn. *J Hosp Infect* 2010;76:225-30.

8. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992;20:864-74.PMID: 20692067.
9. Zorrilla-Vaca A, Arevalo JJ, Escand on-Vargas K, Soltanifar D, Mirski MA. Infectious disease risk associated with contaminated propofol anesthesia, 1989-2014(1). *Emerg Infect Dis* 2016;22:981-92.PMID: 27192163; PMCID: PMC4880094.
10. Ersoz G, Uguz M, Aslan G, Horasan ES, Kaya A. Outbreak of meningitis due to *Serratia marcescens* after spinal anaesthesia. *J Hosp Infect* 2014;87:122-5.PMID: 24814159.
11. Us E, Kutlu HH, Tekeli A, Ocal D, Cirpan S, Memikoglu KO. Wound and soft tissue infections of *Serratia marcescens* in patients receiving wound care: a health care associated outbreak. *Am J Infect Control* 2017;45:443-7.PMID: 28063729.
12. Liu D, Zhang LP, Huang SF, Wang Z, Chen P, Wang H, et al. Outbreak of *Serratia marcescens* infection due to contamination of multiple-dose vial of heparinsaline solution used to flush deep venous catheters or peripheral trocars. *J Hosp Infect* 2011;77:175-6.PMID: 21194795.
13. Chemaly RF, Rathod DB, Sikka MK, Hayden MK, Hutchins M, Horn T, et al. *Serratia marcescens* bacteremia because of contaminated prefilled heparin and saline syringes: a multi-state report. *Am J Infect Control* 2011;39:521-4.PMID: 21492963.
14. Arslan U, Erayman I, Kirdar S, Yuksekkaya S, Cimen O, Tuncer I, et al. *Serratia marcescens* sepsis outbreak in a neonatal intensive care unit. *Pediatr Int* 2010;52:208-12.PMID: 19664012.
15. de Boer MG, Brunsveld-Reinders AH, Salomons EM, Dijkshoorn L, Bernards AT, van den Berg PC, et al. Multifactorial origin of high incidence of *Serratia marcescens* in a cardiothoracic ICU: analysis of risk factors and epidemiological characteristics. *J Infect* 2008;56:446-53. PMID: 18511122.